GLOW & KLOWProtocols for Anti-Aging & Skin Health

Two pre-mixed peptide blends designed for the same goal — rebuilding the structural scaffold of skin (collagen, elastin, the connective matrix that determines firmness and texture) — through different strategies. GLOW provides the structural foundation. KLOW adds inflammation control for reactive or sensitized skin.

Both use a three-phase protocol: daily activation, daily remodeling, then pulsed maintenance. The difference is one compound.

GLOW or KLOW: Which one is right for you?

You can alternate between them based on skin condition. Some practitioners use KLOW during active flares and GLOW during stable periods.

What's in Each Vial

GLOW — BPC-157 + TB-4 + GHK-Cu

KLOW — BPC-157 + TB-4 + GHK-Cu + KPV

The 50/10/10 Ratio

GHK-Cu dominates because collagen production is the continuous demand throughout the protocol. BPC-157 and TB-4 are precision signals — they establish infrastructure and coordinate migration at lower doses. The ratio is designed for cosmetic applications, not injury recovery. (For injury-appropriate dosing, see the GLOW/KLOW for Injuries guide.)

Reconstitution & Dosing

GLOW Vial

KLOW Vial

See the Reconstitution Guide for technique. The peptide dosing calculator can verify injection volumes.

How They Work

Tissue repair proceeds through overlapping phases: inflammation control, barrier stabilization, cell migration, and matrix remodeling. Each component in these blends aligns with a different phase.

GHK-Cu — The Architect

A copper-binding tripeptide that switches on over 4,000 genes involved in tissue repair — collagen production, antioxidant defense, wound healing — while switching off genes linked to inflammation and tissue breakdown. Circulating levels decline with age: roughly 200 ug/mL at age 20, dropping to 80 ug/mL by age 60.

GHK-Cu's bidirectional matrix regulation is its distinguishing feature — it doesn't just add collagen on top of damaged tissue. It remodels what's there while building quality replacement.

BPC-157 — The Infrastructure Builder

A 15-amino-acid fragment from gastric juice that stabilizes tissue barriers and establishes the vascular network needed for active regeneration.

BPC-157 creates the blood vessel network that GHK-Cu's collagen machinery needs. Without blood flow reaching the treatment area, collagen synthesis has raw materials but no delivery system.

TB-4 — The Organizer

Full-length thymosin beta-4 (43 amino acids) — the protein that controls how repair cells move and organize within tissue. TB-4 determines whether healing is coordinated or chaotic.

Why TB-4, not TB-500: These blends use full-length TB-4, not the TB-500 fragment (amino acids 17-23). The systemic thymosin beta-4 data — dermal, ophthalmic, cardiac models — all use the full peptide. TB-4 is preferred for cosmetic and systemic regeneration. The TB-500 fragment is reserved for acute, localized injury repair in separate protocols. Most commercially sold "TB-500" is actually full-length TB-4 regardless of label.

KPV — The Inflammation Switch (KLOW Only)

A three-amino-acid fragment of alpha-MSH (a natural anti-inflammatory hormone). KPV prevents inflammatory genes from activating in the first place — a more targeted approach than NSAIDs, which block inflammation after it's already started. Normal immune signaling needed for healing stays intact.

Route caveat: KPV's strongest preclinical evidence is for oral delivery to gut tissue, where inflamed intestinal cells actively absorb it via the PepT1 transporter (upregulated during inflammation). Subcutaneous delivery, as in KLOW, bypasses this targeted pathway and distributes KPV systemically. Systemic anti-inflammatory effects at injectable doses remain less characterized than oral or topical routes. The dermatological anti-inflammatory profile is supported by mechanistic data (NF-κB inhibition, mast cell stabilization) and clinical experience, but controlled human trials for SubQ KPV specifically have not been published.

The Synergy

Each compound approaches tissue quality from a different angle. Together they create conditions where repair proceeds as an organized cascade rather than isolated signals competing for resources:

• BPC-157 + TB-4: Vascular infrastructure meets organized cell migration — repair cells have roads AND directions
• GHK-Cu + TB-4: Mobilized fibroblasts receive genetic instructions for quality collagen — not just more collagen, but better collagen
• GHK-Cu + BPC-157: Collagen synthesis has continuous nutrient delivery via new microvascular networks
• KPV + all three (KLOW): Inflammatory noise suppressed so the entire cascade operates without interference

All three base compounds also reduce inflammation through their own mechanisms — GHK-Cu suppresses inflammatory genes, BPC-157 quiets inflammatory signaling, TB-4 shifts immune cells toward repair. KLOW's KPV adds a dedicated, targeted layer on top of this inherent capacity.

Three-Phase Protocol

Both GLOW and KLOW use identical scheduling. The per-injection dose is always 0.15 mL (15 units). Phases adjust frequency, not the mixture.

*KPV only in KLOW formulation

Phase 1: Activation (Weeks 1-4)

Dose: 0.25 mL subcutaneous, daily

GHK-Cu activates collagen production while its copper component enables proper structural cross-linking. BPC-157 builds the network of small blood vessels needed to feed active tissue. TB-4 mobilizes and organizes repair cells. In KLOW, KPV simultaneously suppresses inflammatory interference.

Expected: Skin hydration improves, tone evens, texture softens, redness decreases (particularly with KLOW).

Phase 2: Remodeling (Weeks 5-8)

Dose: 0.25 mL subcutaneous, daily

Same per-injection amounts. All compounds at peak coordinated activity.

GHK-Cu drives maximum collagen production — structural proteins, elastin for bounce-back, and the water-binding molecules that keep skin hydrated from within. BPC-157 maintains blood flow to active tissue. TB-4 coordinates efficient cell organization. Small human dermatology studies report meaningful increases in collagen synthesis and reductions in wrinkle depth over 8-12 weeks.

Expected: Fine lines soften, elasticity improves, visible glow returns, skin thickness increases (measurable via ultrasound).

Phase 3: Maintenance (Weeks 9+)

Dose: 0.25 mL subcutaneous, 2-3x weekly

Pulsed administration maintains regenerative signaling without overwhelming the body's regulatory balance:

• Prevents receptor downregulation — continuous exposure causes receptors to become less responsive. Pulsed dosing maintains sensitivity.
• Allows integration time — the body needs 48-72 hours between doses to organize and cross-link newly synthesized collagen. Constant stimulation can produce disorganized matrix.
• Preserves endogenous capacity — enhances rather than replaces natural repair systems. Sustainable long-term without diminishing returns.

Duration: Ongoing, or quarterly 4-week intensive cycles (return to daily dosing every 3-4 months).

Timeline: What to Expect

Administration

• Route: Subcutaneous (abdomen or thigh)
• Timing: Consistent daily timing; evening preferred (collagen synthesis peaks during deep sleep)
• Sites: Rotate to prevent irritation
• Storage: Refrigerate 2-8C after reconstitution, stable 30 days, protect from light

Supply Planning

Each vial provides 20 doses at 0.15 mL (3 mL BAC water ÷ 0.15 mL per dose):

• Weeks 1-8 (daily): 56 doses = 3 vials
• Weeks 9-12 (2-3x weekly): 8-12 doses = 1 vial
• Total: 3-4 vials for a 12-week protocol

Supporting Factors

Optional adjuncts:

• Red light therapy (630-670 nm): 10-20 min daily
• Microneedling: Every 3-4 weeks during Phase 2
• Topical GHK-Cu (0.5-1%): Non-injection days

When Progress Stalls

1. Check protein intake — collagen needs substrate
2. Check sleep quality — GHK-Cu gene expression peaks overnight
3. Verify injection technique and storage
4. Add vitamin C if not already supplementing
5. If inflammation is clearly limiting results and you're on GLOW, switch to KLOW

Safety & Contraindications

Evidence Quality

The individual components are well-characterized, but no controlled clinical trials have evaluated either GLOW or KLOW as blended formulations in human subjects. Synergy between components is inferred from complementary mechanisms, not demonstrated in combination studies.

FAQ

Related Topics

• GHK-Cu for Skin — GHK-Cu mechanism deep-dive
• GLOW/KLOW for Injuries — Why these ratios fail for injury recovery
• BPC-157 Guide — BPC-157 standalone use
• Wolverine Stack — BPC-157 + TB-500 for injury
• NAD+ Guide — Cellular energy for recovery
• Reconstitution Guide — Technique for all peptide vials
• TB-500 Guide — Thymosin Beta-4 fragment used in injury protocols (distinct from TB-4 in GLOW/KLOW)

References

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018. DOI: 10.3390/ijms19071987
• Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008. PubMed: 18644225
• Sikiric P et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des 2018. PubMed: 29737246
• Goldstein AL et al. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005. PubMed: 16099219
• Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999. PubMed: 10469299
• Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. J Crohns Colitis 2008. PubMed: 21172189
• Luger TA, Brzoska T. Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis 2007. PubMed: 17921186

Educational content only. These peptides are not FDA-approved — not because of safety concerns, but because natural peptides cannot be patented, making the billion-dollar clinical trial pathway economically nonviable for any commercial sponsor. This is a structural reality of pharmaceutical economics, not a reflection of safety or efficacy. Work with a qualified healthcare provider before using any peptide protocol.